Immunotherapy with Subcutaneous Low-Dose Interleukin-2 and the Pineal Indole Melatonin as a New Effective Therapy in Advanced Cancers of the Digestive Tract
This 1993 clinical trial evaluated the efficacy and tolerability of combining low-dose interleukin-2 (IL-2) with melatonin (MLT) in 35 patients with advanced digestive tract cancers, including colorectal, gastric, hepatocellular, and pancreatic adenocarcinomas. MLT was administered orally at 50 mg daily, starting seven days before IL-2, which was given subcutaneously at
June 26, 2025
No Comments